Synonym
Nifurtoinol; Urfadin; Levantin; BRN 0897492
IUPAC/Chemical Name
3-(Hydroxymethyl)-1-(((5-nitro-2-furanyl)methylene)amino)-2,4-imidazolidinedione
InChi Key
UIDWQGRXEVDFCA-XCVCLJGOSA-N
InChi Code
InChI=1S/C9H8N4O6/c14-5-11-7(15)4-12(9(11)16)10-3-6-1-2-8(19-6)13(17)18/h1-3,14H,4-5H2/b10-3+
SMILES Code
O=C1N(CO)C(CN1/N=C/C2=CC=C([N+]([O-])=O)O2)=O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
268.19
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Germeau F, Van Regemorter G. Etude du nifurtoinol à action prolongée dans les infections urinaires. Etude comparative [Prolonged-action nifurtoinol in urinary infections. Comparative study]. Acta Urol Belg. 1983;51(3):373-8. French. PMID: 6624626.
2: Stricker BH, Blok AP, Claas FH, Van Parys GE, Desmet VJ. Hepatic injury associated with the use of nitrofurans: a clinicopathological study of 52 reported cases. Hepatology. 1988 May-Jun;8(3):599-606. doi: 10.1002/hep.1840080327. PMID: 3371877.
3: Basly JP, Basly I, Bernard M. Electron spin resonance detection of radiosterilization of pharmaceuticals: application to four nitrofurans. Analyst. 1998 Aug;123(8):1753-6. doi: 10.1039/a802719f. PMID: 10071389.
4: Vree TB, Hekster YA, Baars AM, Damsma JE, van der Kleijn E, Bron J. Determination of nitrofurantoin (Furadantine) and hydroxymethylnitrofurantoin (Urfadyn) in plasma and urine of man by means of high-performance liquid chromatography. J Chromatogr. 1979 Jan 1;162(1):110-6. PMID: 762206.
5: Guelen PJ, Boerema JB, Vree TB. Comparative human bioavailability study of macrocrystalline nitrofurantoin and two prolonged-action hydroxymethylnitrofurantoin preparations. Drug Intell Clin Pharm. 1988 Dec;22(12):959-64. doi: 10.1177/106002808802201205. PMID: 3243175.
6: Szozda G, Nowakowska K, Pawluch D. Porównawcza ocena aktywności przeciwbakteryjnej pochodnych nitrofuranu [Comparative evaluation of the antibacterial activity of nitrofuran derivatives]. Pol Tyg Lek. 1987 Aug 3-10;42(31-32):967-9. Polish. PMID: 3120163.
7: Beysens AJ, Kock HC. Een onderzoek naar de frequentie van braken bij een therapie met resp. Furadantine, Furadantine MC en Urfadyn [A study of the frequency of vomiting during therapy with Furadantine, Furadantine MC and Urfadyn]. Pharm Weekbl. 1973 Feb 23;108(8):149-52. Dutch. PMID: 4689668.
8: Baetens P, Ramboer C. Chronic active hepatitis due to hydroxymethylnitrofurantoin in a male patient. Acta Clin Belg. 1984;39(2):85-91. doi: 10.1080/22953337.1984.11718986. PMID: 6741394.
9: Mattelaer JJ. A new urinary antiseptic with prolonged action, urfadyn PL, in the treatment of urinary tract infections. Acta Urol Belg. 1982 Apr;50(2):270-5. PMID: 7113858.
